Cyclerion Therapeutics Inc (NAS:CYCN)
$ 2.7 0.41 (17.98%) Market Cap: 6.75 Mil Enterprise Value: 1.05 Mil PE Ratio: 0 PB Ratio: 0.68 GF Score: 47/100

Cyclerion Therapeutics Inc Investor Webcast Event Transcript

Sep 17, 2019 / 12:00PM GMT
Release Date Price: $278 (+13.01%)
Jessi Rennekamp
Cyclerion Therapeutics Inc. - Investor Relations and Corporate Communications

Good morning everyone and welcome to Cyclerion's investor event focused on Praliciguat in diabetic nephropathy and heart failure with preserved ejection fraction. My name is Jessi Rennekamp. And I work in Cyclerion's Investor Relations and Corporate Communications Department.

We're really excited that you could be here with us today either in person or for those of you on the webcast.

Throughout today's presentation, we will be making forward-looking statements including statements about the timing and potential results of our clinical trials. These statements are based on current expectations and actual results could differ. For more information, please see the risk factors section of our SEC filings on our website, www.cyclerion.com.

We've put together an exciting agenda for today. The event will run until about 10 a.m. with time for Q&A at the end. If you're on the webcast and would like to ask a question,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot